Integrating new metastatic regimens into current standards

This week’s episode will be on many exciting updates were announced at ESMO this October in Berlin from Oct 17-21, 2025, especially in bladder cancer, we continue to make such progress! We discuss key trials in NMIBC (POTOMAC), MIBC (KN-905, IMvigor-011), and metastatic urothelial carcinoma (FORAGER-1, DV + Toripalimab).